Key result
Immobilized IL-6 performed better than the soluble form in enhancing mesenchymal stem cell adhesion to stiffened substrates through the IL-6/SHP2/integrin signaling axis, which coincided with enhanced in vivo engraftment after myocardial infarction.
Why the study?
Poor engraftment limits mesenchymal stem cell transplantation efficacy after myocardial infarction, and whether and how inflammatory cytokines couple with tissue stiffness changes to affect engraftment remained unclear.
Immobilized IL-6 promotes mesenchymal stem cell adhesion to stiffened substrates via the SHP2/integrin α5β1 axis, suggesting that optimal timing of MSC transplantation (days 3 and 21 post-MI) could improve engraftment efficiency.
Mesenchymal stem cells (MSCs) transplantation has demonstrated its potential in repairing infarct heart tissue and recovering heart function after myocardial infarction (MI). However, its therapeutic effect is still limited due to poor MSC engraftment at the injury site whose tissue stiffness and local inflammation both dynamically and rapidly changes after MI. Whether and how inflammatory cytokines could couple with stiffness change to affect MSC engraftment in the infarct zone still remain unclear. In this study, we characterized dynamical stiffness changes of and inflammatory cytokine expression in the infarct region of rat heart within a month after MI. We found that the tissue stiffness of the heart tissue gradually increased and peaked in twenty-one days after MI along with the rapid upregulation of TNF-α, IL-6 and IL1-β in first three days followed by a sharp declination. We further in-vitro demonstrated that immobilized inflammatory cytokine IL-6 performed better than soluble form in enhancing MSC adhesion to stiffened substrate through IL-6/SHP-2/integrin signaling axis. We also confirmed such mechano-immune coupling of tissue stiffness and inflammatory cytokines in modulating MSC engraftment in the rat heart after MI in vivo. Our study provides new mechanistic insights of mechanical-inflammation coupling to improve MSC mechano-sensing and adhesion, potentially benefiting MSC engraftment and its clinical therapy for MI.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) studied Myocardial Infarction. Immobilized IL-6 vs. Soluble IL-6 or no cytokine was evaluated on MSC adhesion and engraftment. Immobilized IL-6 performed better than the soluble form in enhancing mesenchymal stem cell adhesion to stiffened substrates through the IL-6/SHP2/integrin signaling axis, which coincided with enhanced in vivo engraftment after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: